Literature DB >> 24699640

Structure and possible mechanism of the CcbJ methyltransferase from Streptomyces caelestis.

Jacob Bauer1, Gabriela Ondrovičová1, Lucie Najmanová2, Vladimír Pevala1, Zdeněk Kameník2, Július Koštan3, Jiří Janata2, Eva Kutejová1.   

Abstract

The S-adenosyl-L-methionine (SAM)-dependent methyltransferase CcbJ from Streptomyces caelestis catalyzes one of the final steps in the biosynthesis of the antibiotic celesticetin, methylation of the N atom of its proline moiety, which greatly enhances the activity of the antibiotic. Since several celesticetin variants exist, this enzyme may be able to act on a variety of substrates. The structures of CcbJ determined by MAD phasing at 3.0 Å resolution, its native form at 2.7 Å resolution and its complex with S-adenosyl-L-homocysteine (SAH) at 2.9 Å resolution are reported here. Based on these structures, three point mutants, Y9F, Y17F and F117G, were prepared in order to study its behaviour as well as docking simulations of both CcbJ-SAM-substrate and CcbJ-SAH-product complexes. The structures show that CcbJ is a class I SAM-dependent methyltransferase with a wide active site, thereby suggesting that it may accommodate a number of different substrates. The mutation results show that the Y9F and F117G mutants are almost non-functional, while the Y17F mutant has almost half of the wild-type activity. In combination with the docking studies, these results suggest that Tyr9 and Phe117 are likely to help to position the substrate for the methyl-transfer reaction and that Tyr9 may also facilitate the reaction by removing an H(+) ion. Tyr17, on the other hand, seems to operate by helping to stabilize the SAM cofactor.

Entities:  

Keywords:  CcbJ; SAM-dependent methyltransferases; Streptomyces caelestis

Mesh:

Substances:

Year:  2014        PMID: 24699640     DOI: 10.1107/S139900471303397X

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  6 in total

1.  Characterization of Enzymes Catalyzing Transformations of Cysteine S-Conjugated Intermediates in the Lincosamide Biosynthetic Pathway.

Authors:  Richiro Ushimaru; Chia-I Lin; Eita Sasaki; Hung-Wen Liu
Journal:  Chembiochem       Date:  2016-07-19       Impact factor: 3.164

2.  The Structure of the Bifunctional Everninomicin Biosynthetic Enzyme EvdMO1 Suggests Independent Activity of the Fused Methyltransferase-Oxidase Domains.

Authors:  C A Starbird; Nicole A Perry; Qiuyan Chen; Sandra Berndt; Izumi Yamakawa; Lioudmila V Loukachevitch; Emilianne M Limbrick; Brian O Bachmann; T M Iverson; Kathryn M McCulloch
Journal:  Biochemistry       Date:  2018-12-07       Impact factor: 3.162

3.  Studies of lincosamide formation complete the biosynthetic pathway for lincomycin A.

Authors:  Shao-An Wang; Chia-I Lin; Jiawei Zhang; Richiro Ushimaru; Eita Sasaki; Hung-Wen Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-21       Impact factor: 11.205

4.  Burkholderia glumae ToxA Is a Dual-Specificity Methyltransferase That Catalyzes the Last Two Steps of Toxoflavin Biosynthesis.

Authors:  Michael K Fenwick; Benjamin Philmus; Tadhg P Begley; Steven E Ealick
Journal:  Biochemistry       Date:  2016-05-03       Impact factor: 3.162

5.  Lincosamide synthetase--a unique condensation system combining elements of nonribosomal peptide synthetase and mycothiol metabolism.

Authors:  Jiri Janata; Stanislav Kadlcik; Marketa Koberska; Dana Ulanova; Zdenek Kamenik; Petr Novak; Jan Kopecky; Jitka Novotna; Bojana Radojevic; Kamila Plhackova; Radek Gazak; Lucie Najmanova
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

6.  Deacetylation of mycothiol-derived 'waste product' triggers the last biosynthetic steps of lincosamide antibiotics.

Authors:  Zdenek Kamenik; Stanislav Kadlcik; Bojana Radojevic; Petra Jiraskova; Marek Kuzma; Radek Gazak; Lucie Najmanova; Jan Kopecky; Jiri Janata
Journal:  Chem Sci       Date:  2015-10-01       Impact factor: 9.825

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.